ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• The apolipoprotein E ɛ4 (apoE4) allele is a significant genetic risk factor for Alzheimer's disease (AD).
• apoE4 is characterized by reduced lipidation, contributing to AD pathology.
• Selective activation of ABCA1 (ATP-binding cassette transporter A1) is a potential therapeutic strategy.

Purpose of the Study:

• To investigate the efficacy of CS-6253, a direct ABCA1 activator, in improving apoE4 lipidation in vivo.
• To determine if CS-6253 can counteract apoE4-associated neuropathological and cognitive deficits.

Main Methods:

• Utilized apoE4-targeted replacement mice.
• Administered the peptide CS-6253 to assess its effects on apoE4 lipidation.
• Evaluated Aβ42 accumulation, tau hyperphosphorylation, synaptic markers, and cognitive function.

Main Results:

• CS-6253 treatment significantly increased apoE4 lipidation in mice.
• This increase in lipidation was associated with reduced Aβ42 and hyperphosphorylated tau in the brain.
• Synaptic impairments and cognitive deficits were reversed following CS-6253 administration.

Conclusions:

• The pathological effects of apoE4 are linked to impaired ABCA1 activation and apoE4 lipidation.
• Targeting ABCA1 with agonists like CS-6253 offers a promising therapeutic approach for apoE4-related Alzheimer's disease.
• ABCA1 represents a viable therapeutic target for mitigating apoE4-driven AD pathologies.